<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht004631.v1" study_id="phs000892.v1" participant_set="1" date_created="Thu Aug 13 11:42:43 2015"><description>Participant ID, ethnicity, race, gender, aliquots plasma, family history of health and disease events including colon or rectal cancer, participant history of colon polyps, prior malignancy, new tumor event, and synchronous colon and rectal cancer, history of participant received tumor treatment including chemotherapy, tumor characteristics including tumor pathology, BRAF, KRAS, NRAS&lt; MLH1, MSH2, MSH6 analysis, tumor histology, lymph node examination, detection of microsatellite instability in tumor, venipuncture, Case Report Form, new tumor diagnostic method, method of sample collection, participant weight and height, pathologic diagnosis, tumor stage, CEA level, vital status, participant pharmaceutical treatment, radiation treatment, surgery for the new tumor, targeted molecular therapy, post-operative pharmaceutical therapy,  post-operative radiation therapy, post-operative targeted molecular therapy, anesthesia time of participants with colon tumors and involved in the "Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomic Confirmatory Study of Breast, Colon, Lung, and Ovarian Tumors" project.</description><unique_key phv="00225341" version="1">Participant_ID</unique_key><unique_key phv="00225342" version="1">CRF_Name</unique_key><variable id="phv00225341.v1"><name>Participant_ID</name><description>De-Identified subject (participant) ID, from the pre-printed labels that are part of the procurement package provided by the BCR.</description><type>string</type></variable><variable id="phv00225342.v1"><name>CRF_Name</name><description>Information collected on Case Report Form (CRF) at [Submission; Baseline; 1 year follow-up; 5 year follow-up]</description><type>string</type></variable><variable id="phv00225343.v1"><name>Participant_Procurement_Age</name><description>Provide the participant age in months at the time of tissue procurement.</description><type>number</type><unit>Months</unit></variable><variable id="phv00225344.v1"><name>Participant_Gender</name><description>Participant gender using the defined categories. [Male; Female; Unknown; Unspecified]</description><type>string</type></variable><variable id="phv00225345.v1"><name>Participant_Race</name><description>Participant race using the defined categories. Options = American Indian or Alaska Native;  Asian; White; Black or African American; Native Hawaiian or other Pacific Islander; Not Evaluated; Unknown (Could not be determined or unsure).</description><type>string</type></variable><variable id="phv00225346.v1"><name>Participant_Ethnicity</name><description>Ethnicity using the defined categories. [Not Hispanic or Latino; Hispanic or Latino; Not Evaluated; Unknown]</description><type>string</type></variable><variable id="phv00225347.v1"><name>Participant_History_Malignancy</name><description>Indicate whether the participant has a history of prior malignancies. Note 1: If this question cannot be answered because the answer is unknown, the case will be excluded from CPTAC. Note 2: If the participant has any history of prior malignancies, please complete an Other Malignancy Form for each malignancy diagnosed prior to the procurement of the tissue submitted for CPTAC. If the participant has a history of multiple diagnoses of basal cell skin cancers, complete an Other Malignancy Form for the first diagnosis for each of these types. [No; Yes, Only Basal Cell Skin Cancer Within the Last Year; Yes, History of Other Cancer Greater Than One Year Ago]</description><type>string</type></variable><variable id="phv00225348.v1"><name>Participant_History_Chemotherapy</name><description>Did participant ever received systematic chemotherapy for any previous cancer. [No; Yes]</description><type>string</type></variable><variable id="phv00225349.v1"><name>Participant_History_Neo-adjuvant_Treatment</name><description>Did participant received therapy for this cancer prior to sample procurement of the tumor submitted for CPTAC.  If the participant did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instructions. Note: Systemic treatment and certain localized therapies (those administered to the same site as the CPTAC submitted tissue) given prior to procurement of the sample submitted for CPTAC are exclusionary. [Yes; Yes, Pharmaceutical Treatment Prior to Resection; Yes, Radiation Prior to Resection; Yes, Both Radiation and Pharmaceutical Treatment Prior to Resection; No]</description><type>string</type></variable><variable id="phv00225350.v1"><name>Aliquots_Plasma</name><description>Number of tubes of plasma obtained from the participant.</description><type>number</type><unit>Number of tubes</unit></variable><variable id="phv00225351.v1"><name>Blood_Collection_Time</name><description>The 24-hr clock time on the day of when the CPTAC blood sample(s) was/were collected from the participant.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225352.v1"><name>Blood_Collection_Method</name><description>Method for obtaining the blood sample. [Venipuncture (Vacutainer Apparatus); Venipuncture (Syringe); IV Catheter ]</description><type>string</type></variable><variable id="phv00225353.v1"><name>Anesthesia_Time</name><description>Time when anesthesia was administered to the participant.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225354.v1"><name>Mesentary_Divided_Time</name><description>The 24-hr clock time of when the mesentery containing the tumor was divided.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225355.v1"><name>Tumor_Sample_Number</name><description>Specify the number of segments of the tumor that were removed and saved to the CPTAC-provided cryomolds.</description><type>number</type><unit>Number of segments</unit></variable><variable id="phv00225356.v1"><name>Tumor_Sample_1_Weight</name><description>Weight of tumor segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225357.v1"><name>Tumor_Sample_1_LN2_Time</name><description>The 24-hour clock time when tumor segment 1 was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225358.v1"><name>Tumor_Sample_2_Weight</name><description>Weight of tumor segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225359.v1"><name>Tumor_Sample_2_LN2_Time</name><description>The 24-hour clock time when the tumor segment 2 was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225360.v1"><name>Tumor_Sample_3_Weight</name><description>Weight of tumor segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225361.v1"><name>Tumor_Sample_3_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225362.v1"><name>Tumor_Sample_4_Weight</name><description>Weight of tumor segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225363.v1"><name>Tumor_Sample_4_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225364.v1"><name>Tumor_Sample_5_Weight</name><description>Weight of tumor segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225365.v1"><name>Tumor_Sample_5_LN2_Time</name><description>The 24-hour clock time when the tumor sample or portion  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225366.v1"><name>Normal_Sample_Number</name><description>Specify the number of normal segments that were removed and saved to the CPTAC-provided cryomolds.</description><type>number</type><unit>Number on normal segments</unit></variable><variable id="phv00225367.v1"><name>Normal_Sample_1_Weight</name><description>Weight of normal segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225368.v1"><name>Normal_Sample_1_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225369.v1"><name>Normal_Sample_2_Weight</name><description>Weight of normal segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225370.v1"><name>Normal_Sample_2_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225371.v1"><name>Normal_Sample_3_Weight</name><description>Weight of normal segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225372.v1"><name>Normal_Sample_3_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225373.v1"><name>Normal_Sample_4_Weight</name><description>Weight of normal segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225374.v1"><name>Normal_Sample_4_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225375.v1"><name>Normal_Sample_5_Weight</name><description>Weight of normal segment in mg.</description><type>number</type><unit>mg</unit></variable><variable id="phv00225376.v1"><name>Normal_Sample_5_LN2_Time</name><description>The 24-hour clock time when the normal segment  was immersed in LN2 vapor.</description><type>number</type><unit>(HR(24):MN)</unit></variable><variable id="phv00225378.v1"><name>Primary_Site_Disease</name><description>Using the participant pathology/laboratory report, select the anatomic site of disease of the tumor submitted for CPTAC. [Colon]</description><type>string</type></variable><variable id="phv00225379.v1"><name>Histological_Subtype</name><description>Using the participant pathology/laboratory report, select the histology of the tumor submitted for CPTAC. [Mucinous; Not Mucinous]</description><type>string</type></variable><variable id="phv00225380.v1"><name>Colon_Sub-sites</name><description>Using the participant pathology/laboratory report, select the anatomic organ subdivision of the tumor submitted for CPTAC. [Cecum; Ascending Colon; Hepatix Flexure; Tranverse Colon; Splenic Flexure; Descending Colon; Sigmoid Colon]</description><type>string</type></variable><variable id="phv00225381.v1"><name>Rectum_Sub-sites</name><description>Using the patient pathology/laboratory report, select the anatomic organ subdivision of the tumor submitted for CPTAC. [Rectum; Rectosigmoid Junction]</description><type>string</type></variable><variable id="phv00225382.v1"><name>Pathologic_Spread_Primary_Tumor</name><description>Code for the pathologic T (primary tumor) as defined by the American Joint Committee on Cancer (AJCC).  [T1; T2; T3; T4; T4a; T4b]</description><type>string</type><unit>Pathologic codes of primary tumor</unit></variable><variable id="phv00225383.v1"><name>Pathologic_Spread_Lymph_Nodes</name><description>Code for the pathologic N (nodal) as defined by the American Joint Committee on Cancer (AJCC). [NX; N0; N1; N1a; N1b; N1c; N2; N2a; N2b; N3]</description><type>string</type><unit>Pathologic nodal codes</unit></variable><variable id="phv00225384.v1"><name>Pathologic_Spread_Distant_Metastases</name><description>Code for the pathologic M (metastasis) as defined by the American Joint Committee on Cancer (AJCC).  [MX; M0; M1]</description><type>string</type><unit>Pathologic metastasis codes</unit></variable><variable id="phv00225385.v1"><name>Tumor_Stage_Pathological</name><description>Using the participant pathology/laboratory report, in conjunction with the participant medical record, select the stage as defined by the American Joint Committee on Cancer (AJCC). [Stage I; Stage II; Stage IIA; Stage IIB; Stage IIC; Stage III; Stage IIIA]</description><type>string</type><unit>Pathological tumor stage</unit></variable><variable id="phv00225386.v1"><name>Residual_Tumor</name><description>Using the pathology/laboratory report, select the tissue margin status at the time of surgical resection for the tumor submitted for CPTAC. [ R0; R1; R2; RX]</description><type>string</type></variable><variable id="phv00225387.v1"><name>Lymph_Nodes_Examined</name><description>Indicate whether any lymph nodes were examined at the time of the primary resection for the tumor submitted to CPTAC. [No; Yes]</description><type>string</type></variable><variable id="phv00225388.v1"><name>Lymph_Nodes_Examined_Number</name><description>Number of lymph nodes pathologically assessed if one or more lymph nodes were removed.</description><type>number</type><unit>Number of lymph nodes</unit></variable><variable id="phv00225389.v1"><name>Lymph_Nodes_Positive_Hematoxylin_Eosin_Staining_Number</name><description>Number of lymph nodes identified as positive through hematoxylin and eosin (H&amp;E) staining and light microscopy.</description><type>number</type><unit>Number of lymph nodes</unit></variable><variable id="phv00225390.v1"><name>Lymph_Nodes_Positive_IHC_Keratin_Staining_Number</name><description>Provide the number of lymph nodes identified as positive through keratin immunohistochemistry (IHC) staining.</description><type>number</type><unit>Number of lymph nodes</unit></variable><variable id="phv00225391.v1"><name>Preoperative_or_Pretreatment_CEA_Level</name><description>Carcinoembryonic antigen or CEA level (ng/ml) prior to the resection of tumor submitted to CPTAC.</description><type>number</type><unit>ng/ml</unit></variable><variable id="phv00225392.v1"><name>Circumferential_Resection_Margin_CRM</name><description>Measured length (mm) between a malignant lesion of the colon or rectum and the nearest radial (or circumferential) border of tissue removed during surgery for the tumor submitted to CPTAC.</description><type>number</type><unit>mm</unit></variable><variable id="phv00225393.v1"><name>Vascular_Invasion_Present</name><description>Indicate if large vessel or venous invasion was pathologically present in the tumor specimen submitted to CPTAC. [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225394.v1"><name>Lymphatic_Invasion_Present</name><description>Indicate if malignant cells are pathologically present in small or thin walled vessels suggesting lymphatic involvement in the tumor submitted to CPTAC. [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225395.v1"><name>Perineural_Invasion_Present</name><description>Indicate if perineural invasion or infiltration of tumor or cancer is pathologically present in tumor submitted to CPTAC. [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225396.v1"><name>Synchronous_Colon_Rectal_Tumors</name><description>Indicate whether the participant had a synchronous colon or rectal cancer present at the time tissue was procured for CPTAC.  [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225397.v1"><name>Colon_Polyps_History</name><description>Indicate if the participant had a previous history of colon polyps as noted in the history/physical or previous endoscopic report(s). [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225398.v1"><name>Colon_Polyps_Present</name><description>Indicate if polyps were present in the colon, surgically and/or pathologically, at the time of tissue collection for the tumor submitted to CPTAC. [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225399.v1"><name>Participant_Weight</name><description>Provide the weight of the participant measured in kilograms.</description><type>number</type><unit>kg</unit></variable><variable id="phv00225400.v1"><name>Participant_Height</name><description>Provide the height of the participant in centimeters.</description><type>number</type><unit>cm</unit></variable><variable id="phv00225401.v1"><name>First_Degree_Relatives_with_Colon.Rectal_Cancer</name><description>The number of first degree relatives (parent, sibling and/or child) associated with a diagnosis of colon or rectal cancer.</description><type>string</type><unit>Number of first degree relatives</unit></variable><variable id="phv00225402.v1"><name>First_Degree_Relatives</name><description>Total number of first degree relatives (parents, sibling and/or children) .  A record of a participant background regarding health and disease events of blood relatives. A participant family medical history may be important in diagnosing existing conditions.</description><type>number</type></variable><variable id="phv00225403.v1"><name>Microsatellite_Instability_Abnormal</name><description>Indicate whether microsatellite instability was present in more than 33% of loci tested in the tumor submitted to CPTAC. [Yes; No; Unknown; Not Tested]</description><type>string</type></variable><variable id="phv00225404.v1"><name>MSI_Loci_Tested</name><description>If microsatellite instability was identified, indicate the number of loci tested to detect recessive mutations in the tumor submitted to CPTAC.</description><type>number</type><unit>Number of loci</unit></variable><variable id="phv00225405.v1"><name>MSI_Loci_Abnormal</name><description>Number of loci found to be abnormal during testing to detect microsatellite instability in the tumor submitted to CPTAC.</description><type>number</type><unit>Number of loci</unit></variable><variable id="phv00225406.v1"><name>IHC_Mismatch_Repair_Proteins_Tested</name><description>Was testing performed to identify any loss of expression in mismatch repair proteins tested by immunohistochemistry (IHC)? Note: If not performed, skip to question 50 KRAS Gene Analysis Performed. [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225407.v1"><name>Gene_Espression_MLH1</name><description>Indicate any loss of expression of mismatch repair proteins by immunohistochemistry (IHC) is or is not expressed for each of the listed genes. [MLH1-not tested; MLH1-not expressed; MLH1-expressed]</description><type>string</type></variable><variable id="phv00225408.v1"><name>Gene_Espression_MSH2</name><description>Indicate any loss of expression of mismatch repair proteins by immunohistochemistry (IHC) is or is not expressed for each of the listed genes. [MLH2-not tested; MLH2-not expressed; MLH2-expressed]</description><type>string</type></variable><variable id="phv00225409.v1"><name>Gene_Espression_PMS2</name><description>Indicate any loss of expression of mismatch repair proteins by immunohistochemistry (IHC) is or is not expressed for each of the listed genes. [PMS2-not tested; PMS2-not expressed; PMS2-expressed]</description><type>string</type></variable><variable id="phv00225410.v1"><name>Gene_Espression_MSH6</name><description>Indicate any loss of expression of mismatch repair proteins by immunohistochemistry (IHC) is or is not expressed for each of the listed genes. [MLH6-not tested; MLH6-not expressed; MLH6-expressed]</description><type>string</type></variable><variable id="phv00225411.v1"><name>Gene_Analysis_KRAS</name><description>Indicate if KRAS gene analysis was performed on tumor submitted for CPTAC. Note: If not performed, skip to question 53 BRAF Gene Analysis Performed [Yes; No; Unknown]</description><type>string</type></variable><variable id="phv00225412.v1"><name>Gene_Mutation_Found_KRAS</name><description>If KRAS gene analysis was performed indicate if KRAS Mutation was found. [No; Yes]</description><type>string</type></variable><variable id="phv00225413.v1"><name>Gene_Mutation_Codon_KRAS</name><description>If KRAS mutation was identified indicate the specific codon.</description><type>string</type></variable><variable id="phv00225414.v1"><name>Gene_Mutation_Found_NRAS</name><description>If NRAS gene analysis was performed indicate if NRAS Mutation was found. [No; Yes]</description><type>string</type></variable><variable id="phv00225415.v1"><name>Gene_Mutation_Codon_NRAS</name><description>If NRAS mutation was identified indicate the specific codon.</description><type>string</type></variable><variable id="phv00225416.v1"><name>Gene_Analysis_BRAF</name><description>Indicate if BRAF gene analysis was performed on tumor submitted for CPTAC. Note: If not performed, skip to question 55 Synchronous Colon/Rectal Tumor(s) at Time of Tissue Collection. [No; Yes]</description><type>string</type></variable><variable id="phv00225417.v1"><name>Gene_Analysis_Results_BRAF</name><description>If BRAF gene analysis was performed indicate the result. [Normal; Abnormal, Codon 600; Abnormal, other]</description><type>string</type></variable><variable id="phv00226976.v1"><name>Tumor_Sample_1_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226977.v1"><name>Tumor_Sample_2_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226978.v1"><name>Tumor_Sample_3_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226979.v1"><name>Tumor_Sample_4_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226980.v1"><name>Tumor_Sample_5_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226981.v1"><name>Normal_Sample_1_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226982.v1"><name>Normal_Sample_2_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226983.v1"><name>Normal_Sample_3_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226984.v1"><name>Normal_Sample_4_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable><variable id="phv00226985.v1"><name>Normal_Sample_5_Ischemia_Time</name><description>Calculated ischemia time. The difference between time of immersion in LN2 and  mesentery divided time.</description><type>number</type><unit>Minutes</unit></variable></data_table>
